Related Experiment Video
Updated: Aug 14, 2026

Platelet-based Detection of Nitric Oxide in Blood by Measuring VASP Phosphorylation
Published on: January 7, 2019
Inhibition of phosphodiesterase 5 selectively reverses nitrate tolerance in the venous circulation
Jeffery D MacPherson1, Timothy D Gillespie, Heather A Dunkerley
1Department of Pharmacology and Toxicology, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.
Abstract:
An important component of the antianginal efficacy of glyceryl trinitrate (GTN) is attributable to its selective venodilator effect, resulting in decreased cardiac preload and myocardial oxygen demand. Tolerance to nitrates occurs during chronic exposure, and the current study assessed whether this was due to increased phosphodiesterase (PDE) activity in the venous circulation. Tolerance was induced in rats by continuous exposure to 0.4 mg/h GTN for 48 h. Tension recordings of isolated femoral artery and vein indicated that tolerance was more pronounced in femoral vein. 4-[[3,4-(Methylenedioxy)benzyl]amino]-6-chloroquinazoline (MBCQ), a selective PDE5 inhibitor, significantly decreased the EC(50) values for GTN-induced relaxation in both tolerant and nontolerant tissues, but with the greatest relative shift occurring in tolerant veins. MBCQ also increased the vasodilator potency of 1,1-diethyl-2-hydroxy-2-nitrosohydrazine (DEA/NO), a nitric oxide donor; however, cross-tolerance between DEA/NO and GTN was not observed. A significant increase in cGMP PDE activity was observed in tolerant femoral vein, whereas PDE activity was unchanged in femoral artery. Conscious rats treated with hexamethonium (30 mg/kg) to induce ganglionic blockade exhibited blunted central venous pressure (CVP) and mean arterial pressure (MAP) responses to bolus i.v. doses of GTN in GTN-tolerant animals. The cGMP PDE inhibitor zaprinast (1 mg/kg) selectively reversed the blunted CVP response to GTN in tolerant animals but had no effect on the CVP response to GTN in nontolerant animals or on the MAP response in either group. These results suggest that increased PDE5 activity in the venous circulation contributes to the altered hemodynamic response to GTN following chronic GTN exposure.
Insights
Tolerance to glyceryl trinitrate (GTN) involves increased phosphodiesterase (PDE) activity in veins. This study shows PDE5 inhibition can restore GTN
Area of Science:
- Pharmacology
- Cardiovascular Physiology
- Nitrate Tolerance
Background:
- Glyceryl trinitrate (GTN) is an antianginal drug with a key venodilator effect.
- Chronic GTN exposure can lead to tolerance, reducing its efficacy.
- The mechanism of nitrate tolerance, particularly in the venous circulation, requires further investigation.
Purpose of the Study:
- To investigate the role of phosphodiesterase (PDE) activity in the development of GTN tolerance.
- To determine if increased PDE activity in the venous circulation contributes to altered hemodynamic responses to GTN.
Main Methods:
- Induction of GTN tolerance in rats via continuous GTN exposure.
- Tension recordings of isolated rat femoral artery and vein.
- Assessment of GTN-induced relaxation using PDE5 inhibitors (MBCQ and zaprinast).
- Measurement of cyclic guanosine monophosphate (cGMP) PDE activity in vascular tissues.
- Evaluation of hemodynamic responses (CVP and MAP) to GTN in conscious, ganglionic-blocked rats.
Main Results:
- GTN tolerance was more pronounced in the femoral vein compared to the artery.
- The PDE5 inhibitor MBCQ shifted the GTN dose-response curve significantly, especially in tolerant veins.
- cGMP PDE activity increased in tolerant femoral veins but not in arteries.
- The PDE inhibitor zaprinast selectively reversed blunted central venous pressure responses to GTN in tolerant rats.
Conclusions:
- Increased PDE5 activity in the venous circulation is a significant factor contributing to GTN tolerance.
- Targeting PDE5 may be a therapeutic strategy to overcome nitrate tolerance.
- These findings elucidate a key mechanism underlying the diminished antianginal efficacy of GTN during chronic use.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Antihypertensive Drugs: Vasodilators
Nitric Oxide Signaling Pathway
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

